Fostamatinib Slated for EU Approval in Chronic ITP

November 15, 2019 – The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for a Marketing Authorization Application of fostamatinib disodium hexahydrate (fostamatinib) for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who are refractory to other treatments. The recommendation is based on findings from the FIT Phase III clinical program, which included the … (leggi tutto)